Results 91 to 100 of about 141,694 (266)
A STUDY OF SPECIFIC CHARACTERISTICS OF HEPATITIS B SURFACE ANTIGEN (HBS.AG) CARRIERS
نشریه پرستاری ایران, 2001 Background : preventing of hepatitis B needs recognition of it's causative agent and specific characteristic. Hospital staffs get most rating for hepatitis B carrier.
Masroor, D +3 more
doaj
پزشکی بالینی ابن سینا, 1997 In this study, all of the voluntary blood donor records-11455 cases-were studied in Hamadan province blood transfusion organization from Feb, 1995 to Jan. 1996.
Masoud Saboori Ghannad +1 more
doaj
A Personalised Vaccination Program Based on Immune Reconstitution in Paediatric Cancer Survivors
Acta Paediatrica, EarlyView.ABSTRACT Aims Paediatric cancer survivors often experience treatment‐induced immunosuppression, requiring post‐treatment revaccination. However, immune recovery timelines vary, and current revaccination guidelines, largely based on data of varied quality derived from studies on acute‐lymphoblastic‐leukaemia (ALL), may not be applicable across all ...
Menucha Jurkowicz +17 more
wiley +1 more source
Alimentary Pharmacology &Therapeutics, EarlyView.In 59,946 chronic hepatitis B patients followed over 23 years, COVID‐19 vaccination rollout was temporally associated with a 56% increase in HBsAg loss rates (peak 1.27 per 100 person‐years in 2022), followed by gradual waning. Negative control outcomes showed no similar pattern, supporting biological specificity. ABSTRACT Background and Aims Hepatitis
Jonggi Choi +6 more
wiley +1 more source
Asian Journal of Medical SciencesBackground: The management of chronic hepatitis B (CHB) infection is complex due to its natural history, which includes fluctuating viral replication and associated hepatic dysfunction.
Diksha Budhani +4 more
doaj +1 more source
Alimentary Pharmacology &Therapeutics, EarlyView.HBV reactivation incidence varied across immunosuppressive and chemotherapeutic agents. Clinically meaningful HBV reactivation was also observed in patients receiving corticosteroids and conventional immunosuppressive therapies. ABSTRACT Background Data on the incidence of hepatitis B virus reactivation (HBVr) remain limited. In Japan, patients who are
Kazuhiko Ikeuchi +8 more
wiley +1 more source
Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt
British Journal of Pharmacology, EarlyView.Abstract Covalent drug discovery is currently experiencing a boom in industrial and academic interest. To date, at least 75 covalent drugs have received regulatory approval, targeting both traditional target classes and more challenging proteins for which other approaches failed. In many cases, unique aspects of covalent targeting are essential for the
Charles P. Brown +2 more
wiley +1 more source
Therapeutic potential of natural products in cancer immunotherapy: Advances and challenges
British Journal of Pharmacology, EarlyView.This review systematically outlines the mechanisms underlying tumour immunotherapy resistance and elucidates the role of natural products in enhancing therapeutic efficacy as immunomodulatory adjuvants. Abstract Immunotherapy has emerged as a clinically pivotal approach in cancer treatment, but its application remains limited to a small subset of ...
Rao Hu +6 more
wiley +1 more source
Cancer Science, EarlyView.OncoVV‑shHSP70, a vaccinia virus silencing HSP70, demonstrated potent antitumor efficacy in colorectal cancer cell lines, as well as in syngeneic, xenograft, and humanized mouse models. In cell lines, oncoVV‑shHSP70 promoted viral oncolysis and cytokine production through a self‑reinforcing cycle of ROS‑autophagy. In both CT26 and SW620‑humanized mouse
Rentao Yuan +8 more
wiley +1 more source